Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
This article reviews the current role of bevacizumab in the management of mCRC, the possible barriers associated with diminished access to bevacizumab, and the potential bevacizumab biosimilars in development. How biosimilars may impact the treatment of mCRC is also discussed.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | Insurance | Lung Cancer | Non-Small Cell Lung Cancer